BLRX - BioLineRx Ltd.
After hours:
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.5500 |
| Open | 1.5600 |
| Bid | 1.4100 x 1000 |
| Ask | 1.5500 x 1000 |
| Day's Range | 1.3900 - 1.5600 |
| 52 Week Range | 0.5500 - 1.9800 |
| Volume | |
| Avg. Volume | 506,740 |
| Market Cap | 92.296M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ:AXSM), for example. At one time, it was a $2.50 stock. Now it’s up to $71 with a treatment for major depressive disorder. Fate Therapeutics (NASDAQ:FATE) once traded at less than $2.50, and ran to more than $114. Novavax (NASDAQ:NVAX) once traded around $3. All of them started small, but their strong pipelines didn’t let them stay cheap for long. In fact, find a biotech with
- InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for April
Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided. And, as pointed out by the U.S. Securities and Exchange Commission (SEC), “Penny stocks may trade infrequently – which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accuratel
- Insider Monkey
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 Financial Results Conference Call. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications BioLineRx. Please go ahead. John Lacey: Thank […]
- Benzinga
BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate
BioLineRx Ltd (NASDAQ: BLRX) announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable metastatic solid tumors. The study met its primary endpoint of AGI-134's safety and tolerability. In this first-in-human trial, 38 patients were treated with AGI-134. Part 1 demonstrated that AGI-134 was safe and well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached, and the recommended dose for
- Benzinga
BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer
BioLineRx Ltd (NASDAQ: BLRX) entered into a $40 million non-dilutive secured debt financing agreement with Kreos Capital. Per the terms of the agreement, the first tranche of $10 million was made available to BioLineRx upon execution of the definitive agreement. The remaining $30 million will be made available in two additional tranches subject to achieving pre-specified milestones. The tranches are available for drawdown at BioLineRx's discretion at various time points through October 1, 2024.
